Please login to the form below

Not currently logged in

difficult-to-treat cancers

This page shows the latest difficult-to-treat cancers news and features for those working in and with pharma, biotech and healthcare.

Regeneron set to acquire Checkmate for approximately $250m

Regeneron set to acquire Checkmate for approximately $250m

a promising new modality to Regeneron's toolkit of potential approaches for difficult-to-treat cancers. ... We look forward to welcoming the Checkmate team and their complementary scientific acumen to the Regeneron family.".

Latest news

More from news
Approximately 1 fully matching, plus 22 partially matching documents found.

Latest Intelligence

  • BiTE* platform and the evolution toward off-the-shelf immuno-oncology approaches BiTE* platform and the evolution toward off-the-shelf immuno-oncology approaches

    Amgen Oncology, one of the leading developers of innovative therapies for novel targets in difficult-to-treat cancers, is working to bring new hope for transforming clinical outcomes for patients with ... Visit to learn more about the

  • A snapshot of Crescendo Biologics A snapshot of Crescendo Biologics

    What is the central focus of Crescendo’s research? The company is focused on T-cell enhancement to develop new ways to treat difficult cancer types. ... success – or to make advances in those cancers that are still difficult to treat in this way.

  • Radiosurgery innovation

    Radiosurgery has greatest application in patients with difficult-to-treat cancers such as brain tumours. ... This was a tough ask of Pegasus as our technology is highly complex and it can be difficult to get journalists to understand its potential, let

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Subscribe to our email news alerts

Featured jobs


Add my company
Fishawack Health

Fishawack Health is the leading global commercialization partner for the modern life science era. Established in 2001 and headquartered in...

Latest intelligence

Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....